onconocimiento.net
Bienvenidos al Portal de Onconocimiento - ONCONOCIMIENTO - Foro de pacientes del cáncer
Plan Integral de Oncología de Andalucía - ONCOnocimiento - Foro de pacientes con cáncer. Bienvenido a nuestro foro. 13 de abril de 2018, 1:19:20. Es un portal avalado por el Plan Integral de Oncología de Andalucía (PIOA) cuyo objetivo fundamental es difundir el conocimiento sobre el cáncer entre la población y los profesionales sanitarios. En él, los profesionales. Así mismo, los pacientes y familiares. By Complejo Hospitalario Universitario de Granada.
onconome.com
Saving Lives Through Early Cancer Detection | Onconome
In our 2014 clinical trial, samples from over 450 patients were evaluated with our blood test for colon cancer (CRC), ONC107. All of these samples were from subjects screened for CRC by colonoscopy immediately after their blood sample was taken. Using our Mass Spec method, we were able to identify 100% of subjects confirmed to have CRC by colonoscopy. Learn more. Site Design: Lynn Media.
onconomicon.blogspot.com
Onconomicon
Thoughts on sequencing by synthesis, the cancer genome, oncology and the life of two physician scientists in training. Thursday, December 7, 2017. The revolution in immunotherapy is incredibly exciting. Cancers are being treated, and occasionally, apparently, cured, by tweaking a patient's own immune system. It is a thrilling new development, and a hope to millions of people. But we need to show some sobriety. It turns out this totally works! A truly "personalized medicine" is a tall order. We might ...
onconomics.com
ONCONOMICS®
We aim to provide a intelligent platform for the public to seek best care and management for their health. When the patients are faced with the daunting task of what may be the best path forward,. We will support them through decision guidance,treatment navigation and support planning needed to bring them back to health. Health data management and integration, treatment decision guidance, tele-medicine, big data analysis. ONCONOMICS® is a register trademark.
onconomics.net
Main Page - Bio.pe.kr
From Bio.pe.kr. Retrieved from " http:/ onconomics.net/index.php/Main Page. Related Links [ Edit. This page was last modified on 23 March 2015, at 07:29. This page has been accessed 815,204 times. Content is available under BioLicense: the freest license. About Bio.pe.kr.
onconomics.org
ONCONOMICS®
We aim to provide a intelligent platform for the public to seek best care and management for their health. When the patients are faced with the daunting task of what may be the best path forward,. We will support them through decision guidance,treatment navigation and support planning needed to bring them back to health. Health data management and integration, treatment decision guidance, tele-medicine, big data analysis. ONCONOMICS® is a register trademark.
onconord.org
Accueil - Réseau de cancérologie Onconord - Ile de France
Les établissements du réseau. Le territoire d intervention du réseau. Nous faire un don, c est soutenir Onconord dans l ensemble de ses actions. Bienvenue sur le site Internet du Réseau Onconord. Durant les diverses étapes de la maladie, il peut être soigné dans différents lieux. Il est très important que les professionnels communiquent au mieux pour travailler dans le même sens, dans l’intérêt du patient. Les établissements et le territoire dintervention du réseau.
onconostica.com
onconostica.com - onconostica Resources and Information.
onconotes.org
OncoNotes [Article name]
onconova.com
Onconova Therapeutics, Inc. - A Phase 3 stage biopharmaceutical company
INVESTORS & MEDIA. Corporate Events & Presentations. Annual Reports and Proxies. Lead Candidate, Rigosertib, in Phase 3 Trials for Myelodysplastic Syndromes (MDS). A Blood Cancer Resulting From Bone Marrow Failure. Learn more about MDS. More Than 10,000 Patients Currently Have High-risk MDS; A Large Unmet Medical Need. Late-stage Trials Include Stand-alone And Combination Therapies. Learn more about our Clinical Trials. Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused ...
